Výsledky vyhledávání - "Elizabeth A. Lakota"

Drug‐Drug Interaction Studies of Methadone and Antiviral Drugs: Lessons Learned

Autor: Elizabeth A. Lakota, Islam R. Younis, Donna A. Volpe, Vikram Patel, Yun Xu, Chandra Sahajwalla

Publikováno v: The Journal of Clinical Pharmacology. 59:1035-1043

Different views appear in the literature on the extent of specific cytochrome P450 (CYP) involvement in methadone metabolism. The aim of this work is to leverage knowledge from drug-drug interaction (DDI) studies in new drug applications between meth

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::0aff938fce1ab85e5930ebd935b0a313
https://doi.org/10.1002/jcph.1405

Zobrazit plný text záznamu

Population Pharmacokinetic Analyses for Omadacycline Using Phase 1 and 3 Data

Autor: Judith N. Steenbergen, Scott A. Van Wart, Elizabeth A Lakota, M Courtney Safir, Evan Tzanis, Sujata M. Bhavnani, Lawrence V. Friedrich, Christopher M. Rubino, Michael Trang, Paul G. Ambrose

Publikováno v: Antimicrobial Agents and Chemotherapy

Omadacycline, a novel aminomethylcycline antibiotic with activity against Gram-positive and -negative organisms, including tetracycline-resistant pathogens, received FDA approval in October 2018 for the treatment of patients with acute bacterial skin

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4bdb94e29135a314464f2ea5f88dfdde
http://europepmc.org/articles/PMC7318031

Zobrazit plný text záznamu

Pharmacokinetic-Pharmacodynamic Characterization of Omadacycline against Haemophilus influenzae Using a One-Compartment In Vitro Infection Model

Autor: Elizabeth A Lakota, Haley Conde, Judith N. Steenbergen, Lawrence V. Friedrich, Sujata M. Bhavnani, Jennifer McCauley, Paul G. Ambrose, Brian VanScoy

Publikováno v: Antimicrobial Agents and Chemotherapy. 64

Omadacycline is a novel aminomethylcycline with activity against Gram-positive and -negative organisms, including Haemophilus influenzae, which is one of the leading causes of community-acquired bacterial pneumonia (CABP). The evaluation of antimicro

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::b63c528319a4bc59a1d740b3ef27b17e
https://doi.org/10.1128/aac.02265-19

Zobrazit plný text záznamu

Pharmacokinetic-Pharmacodynamic Target Attainment Analyses To Support Dose Selection for ME1100, an Arbekacin Inhalation Solution

Autor: Jeffrey P. Hammel, Elizabeth A Lakota, Yu Nagira, Paul G. Ambrose, Kenichiro Kondo, Nobuo Sato, M Courtney Safir, Sujata M. Bhavnani, Tomokazu Koresawa, Brian VanScoy, Christopher M. Rubino

Publikováno v: Antimicrob Agents Chemother

ME1100 (arbekacin inhalation solution) is an inhaled aminoglycoside that is being developed to treat patients with hospital-acquired and ventilator-associated bacterial pneumonia (HABP and VABP, respectively). Pharmacokinetic-pharmacodynamic (PK-PD)

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::025e09a6747958717fc457a0d8d9aae1
https://pubmed.ncbi.nlm.nih.gov/32661000

Zobrazit plný text záznamu

Pharmacokinetic-Pharmacodynamic Characterization of Omadacycline against Haemophilus influenzae Using a One-Compartment

Autor: Brian D, VanScoy, Elizabeth A, Lakota, Haley, Conde, Jennifer, McCauley, Lawrence, Friedrich, Judith N, Steenbergen, Paul G, Ambrose, Sujata M, Bhavnani

Publikováno v: Antimicrobial Agents and Chemotherapy

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::7e8786fc707ef8e605df2a491574fdd4
https://pubmed.ncbi.nlm.nih.gov/32284378

Zobrazit plný text záznamu

Pharmacokinetic-Pharmacodynamic Evaluation of Ertapenem for Patients with Hospital-Acquired or Ventilator-Associated Bacterial Pneumonia

Autor: Elizabeth A Lakota, Helio S. Sader, Paul G. Ambrose, Justin C Bader, Sujata M. Bhavnani, John H. Rex, Glenn E. Dale

Publikováno v: Antimicrobial Agents and Chemotherapy. 63

Ertapenem provides activity against many pathogens commonly associated with hospital-acquired and ventilator-associated bacterial pneumoniae (HABP and VABP, respectively), including methicillin-susceptible Staphylococcus aureus and numerous Gram-nega

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::890b9160d67593e13dcce445eabbed4b
https://doi.org/10.1128/aac.00318-19

Zobrazit plný text záznamu

Erratum for Lakota et al., 'Population Pharmacokinetic Analyses for Rezafungin (CD101) Efficacy Using Phase 1 Data'

Autor: Christopher M. Rubino, Elizabeth A Lakota, Shawn Flanagan, Voon Ong

Publikováno v: Antimicrobial Agents and Chemotherapy

Rezafungin (CD101) is a novel echinocandin antifungal agent currently in clinical development for the treatment of candidemia and invasive candidiasis. Rezafungin has potent in vitro activity against Candida albicans and Candida glabrata, including a

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6f2faaf4dc4a6441b07c1cb927697112
https://europepmc.org/articles/PMC6437527/

Zobrazit plný text záznamu

Population Pharmacokinetic Analyses for Arbekacin after Administration of ME1100 Inhalation Solution

Autor: Elizabeth A Lakota, Christopher M. Rubino, Kenichiro Kondo, Paul G. Ambrose, Sujata M. Bhavnani, Tomokazu Koresawa, Nobuo Sato

Publikováno v: Antimicrobial agents and chemotherapy. 63(8)

ME1100, an inhalation solution of arbekacin, an aminoglycoside, is being developed for the treatment of hospital-acquired and ventilator-associated bacterial pneumonia. The objective of these analyses was to develop a population pharmacokinetic model

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fcfddd05eade646d911fbd46e4333b81
https://pubmed.ncbi.nlm.nih.gov/31182524

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání